AEVIS VICTORIA SA / Key word(s): AGMEGM
AEVIS VICTORIA SA - Ordinary General Meeting of Shareholders: all proposals approved
For further information:
End of ad hoc announcement
AEVIS VICTORIA SA / Key word(s): AGMEGM
AEVIS VICTORIA SA - Ordinary General Meeting of Shareholders: all proposals approved
For further information:
End of ad hoc announcement
The country added 362,727 new COVID-19 infections over the last 24 hours while deaths climbed by 4,120, taking the toll to 258,317, according to the health ministry.
Dublin, May 13, 2021 (GLOBE NEWSWIRE) -- The "Global Stem Cell Therapy Market by Type (Allogeneic, Autologous), Therapeutic Application (Musculoskeletal, Wound & Injury, CVD, Autoimmune & Inflammatory), Cell Source (Adipose tissue, Bone Marrow, Placenta/Umbilical Cord) - Forecasts to 2026" report has been added to ResearchAndMarkets.com's offering. The global stem cell therapy market is projected to reach USD 401 million by 2026 from USD 187 million in 2021, at a CAGR of 16.5% during the forecast period. Growth in this market is majorly driven by the increasing investment in stem cell research and the rising number of GMP-certified stem cell manufacturing plants.However, factors such as ethical concerns and the high cost of stem cell research and manufacturing process likely to hinder the growth of this market. The allogeneic stem cell therapy segment accounted for the highest growth rate in the stem cell therapy market, by type, during the forecast period The stem cell therapy market is segmented into allogeneic and autologous stem cell therapy. Allogeneic stem therapy segment accounted for the largest share of the stem cell therapy market. The large share of this segment can be attributed to the lesser complexities involved in manufacturing allogeneic-based therapies. This segment is also expected to grow at the highest growth rate due to the increasing number of clinical trials in manufacturing allogeneic-based products. Bone Marrow-derived MSCs segment accounted for the highest CAGR Based on the cell source from which stem cells are obtained, the global stem cell therapy market is segmented into four sources. These include adipose tissue-derived MSCs (mesenchymal stem cells), bone marrow-derived MSCs, placenta/umbilical cord-derived MSCs, and other cell sources (which include human corneal epithelium stem cells, peripheral arterial-derived stem cells, and induced pluripotent stem cell lines). The bone marrow-derived MSCs segment is expected to witness the highest growth rate during the forecast period, owing to an increasing number of clinical trials focused on bone marrow-derived cell therapies and the rising demand for these cells in blood-related disorders. Asia Pacific: The fastest-growing country in the stem cell therapy market The stem cell therapy market is segmented into North America, Europe, Asia Pacific, RoW. The stem cell therapy market in the Asia Pacific region is expected to grow at the highest CAGR during the forecast period. Factors such as the growing adoption of stem cell-based treatment in the region and the growing approval & commercialization of stem cell-based products for degenerative disorders drive the growth of the stem cell therapy market in the region. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights4.1 Stem Cell Therapy Market Overview4.2 North America: Stem Cell Therapy Market4.3 Stem Cell Therapy Market, by Cell Source4.4 Stem Cell Therapy Market: Geographic Growth Opportunities 5 Market Overview5.1 Introduction5.2 Market Dynamics5.2.1 Drivers126.96.36.199 Availability of Funding for Stem Cell Research188.8.131.52 Increasing GMP-Certification Approvals for Cell Therapy Production Facilities184.108.40.206 Increasing Clinical Trials for Stem Cell Based-Therapies5.2.2 Restraints220.127.116.11 Ethical Concerns Related to Embryonic Stem Cells18.104.22.168 High Cost of Cell-Based Research5.2.3 Opportunities22.214.171.124 The Emergence of IPSCs as an Alternative to ESCs126.96.36.199 Growing Demand for Cell & Gene Therapies5.2.4 Challenges188.8.131.52 Technical Limitations5.3 COVID-19 Impact Analysis5.4 Technology Analysis5.5 Value Chain Analysis5.6 Ecosystem Market Map5.7 Supply Chain5.8 Porters Five Forces Analysis5.8.1 Threat of New Entrants5.8.2 Threat of Substitutes5.8.3 Bargaining Power of Suppliers5.8.4 Bargaining Power of Buyers5.8.5 Intensity of Competition Rivalry5.9 Regulatory Landscape5.9.1 North America5.9.2 Europe5.9.3 Asia-Pacific5.9.4 Row5.10 Pricing Analysis5.11 Patent Analysis 6 Stem Cell Therapy Market, by Type6.1 Introduction6.2 Allogeneic Stem Cell Therapy6.2.1 Ease in Production Processes to Drive Market Growth6.3 Autologous Stem Cell Therapy6.3.1 Low Risk of Post-Treatment Complications to Drive the Market Growth 7 Stem Cell Therapy Market, by Cell Source7.1 Introduction7.2 Adipose Tissue-Derived MSCs7.2.1 Advantages of Being Easy to Isolate and Harvest Drives the Market Growth of this Segment7.3 Bone Marrow-Derived MSCs7.3.1 Increasing Cases of Metabolic Disorders to Support Market Growth of this Segment7.4 Placenta/Umbilical Cord-Derived MSCs7.4.1 Low Chances of Rejection from the Immune System is Likely to Support Market Growth of this Segment7.5 Other Cell Sources 8 Stem Cell Therapy Market, by Therapeutic Application8.1 Introduction8.2 Musculoskeletal Disorders8.2.1 Increasing Cases of Osteoarthritis to Drive the Market Growth of this Segment8.3 Wounds & Injuries8.3.1 Increasing Benefits of Allogeneic-Based Therapies to Support the Market Growth8.4 Inflammatory & Autoimmune Diseases8.4.1 Increasing Clinical Trials for this Segment is Likely to Support Market Growth8.5 Surgeries8.5.1 Increasing Clinical Research for Surgical Applications to Support Market Growth8.6 Cardiovascular Diseases8.6.1 Increasing Public & Private Funding for CVD Research is Likely to Support Market Growth8.7 Neurological Disorders8.7.1 Rising Prevalence of Neurogenerative Disorders Supports Market Growth of this Segment8.8 Other Therapeutic Applications 9 Stem Cell Therapy Market, by Region9.1 Introduction9.2 North America9.3 Europe9.4 Asia-Pacific9.5 Rest of the World 10 Competitive Landscape10.1 Overview10.2 Revenue Share Analysis of Top Market Players10.3 Market Share Analysis10.4 Competitive Leadership Mapping10.4.1 Stars10.4.2 Emerging Leaders10.4.3 Pervasive Players10.4.4 Participants10.5 Stem Cell Therapy Market: SME Evaluation Matrix, 2020 (Under Pipeline)10.5.1 Progressive Companies10.5.2 Starting Blocks10.5.3 Responsive Companies10.5.4 Dynamic Companies10.6 Company Product Footprint10.7 Company Geographic Footprint of Major Players in the Stem Cell Therapy Market10.8 Competitive Scenario10.8.1 Product Launches10.8.2 Deals10.8.3 Other Developments 11 Company Profiles11.1 Major Players11.1.1 Smith & Nephew11.1.2 Medipost11.1.3 Anterogen11.1.4 Corestem11.1.5 Pharmicell11.1.6 NuVasive11.1.7 RTI Surgical11.1.8 AlloSource11.1.9 JCR Pharmaceuticals11.1.10 Takeda Pharmaceutical Company11.1.11 Holostem Terapie Avanzate11.1.12 Orthofix11.1.13 Stempeutics Research11.1.14 Regrow Biosciences11.2 Other Players (Under Pipeline)11.2.1 Athersys11.2.2 Mesoblast11.2.3 BioRestorative Therapies11.2.4 Pluristem Theraputics11.2.5 Brainstorm Cell Therapeutics11.2.6 Gamida Cell11.2.7 ViaCyte11.2.8 Kangstem Biotech11.2.9 Hope Biosciences11.2.10 Cellular Biomedicine Group11.2.11 Personalized Stem Cells 12 Appendix12.1 Discussion Guide12.2 Knowledge Store: The Subscription Portal12.3 Available Customizations For more information about this report visit https://www.researchandmarkets.com/r/b510tk CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Company announcement No. 10/2021 13 May 2021 Transactions in connection with share buyback programmeOn 6 May 2021, Netcompany Group A/S (“Netcompany”) announced that a share buyback programme of up to DKK 50m and a maximum of 125,000 shares had been initiated with the purpose of meeting Netcompany’s future commitments under its LTIP programmes (RSU). The share buyback programme is executed in accordance with EU Market Abuse Regulation, EU Regulation no. 596/2014 of 16 April 2014 and the provisions of Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Regulation”). The share buyback programme will end no later than 2 June 2021. Transactions made under the share buyback programme will be announced through Nasdaq Copenhagen on a weekly basis. The following transactions have been executed in the period 6 May 2021 to 12 May 2021: Number of sharesAverage purchase price, DKKTransaction value, DKK06-05-20218,000646.995,175,92007-05-20217,000648.544,539,78010-05-20215,000671.853,359,25011-05-20218,000648.205,185,60012-05-20218,000639.525,116,160Accumulated for the period36,000-23,376,710Accumulated under the programme36,000-23,376,710 Detailed information on all transactions under the share buyback programme during the period is included in the attached appendix. Following the above transactions, Netcompany owns a total of 935,813 treasury shares corresponding to 1.87% of the total share capital. Additional information For additional information, please contact Netcompany Group A/S Thomas Johansen, CFO+45 51 19 32 24 Tine K. Boye, General Counsel+45 24 91 75 33 Attachments 10. Transactions in connection with share buyback programme 10a. Information on all transactions
Ready to give your old laptop the boot? Save big today on a fully loaded refurbished MacBook Pro.
The "Breast Cancer Liquid Biopsy - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
Ten weeks before the start of the Olympics, Tokyo remains in a state of emergency, 60% of the Japanese people do not want the Olympics to go ahead, and only around 3% of them have been vaccinated for COVID-19. Yet the message from the International Olympic Committee, local organisers and the Japanese government has been consistent -- full speed ahead to the opening ceremony on July 23. With IOC President Thomas Bach having made it clear another postponement is not an option, cancellation would be the only alternative to proceeding.
Taxes can be a burden at any stage of life -- both during your working years, as well as in retirement. If you're many years away from retirement, you shouldn't put a ton of money into bonds. Rather, you should focus on buying stocks, which tend to deliver a much higher return than bonds.
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Identity of the person whose positions/dealings are being disclosed:Boussard & Gavaudan Investment Management LLP Boussard & Gavaudan Asset Management LP Boussard & Gavaudan Gestion SAS acting on behalf of various funds(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Equiniti Group Plc (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken:12th May 2021(f) Has the discloser previously disclosed, or are they today disclosing, under the Code in respect of any other party to this offer?No 2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any) Class of relevant security: GBP 0.1p ordinary ISIN: GB00BYWWHR75 InterestsShort positionsNumber%Number%(1) Relevant securities owned and/or controlled: (2) Derivatives CFD (other than options): 4,402,9481.19898% (3) Options and agreements to purchase/sell: TOTAL:4,402,9481.19898% All interests and all short positions should be disclosed. Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions). (b) Rights to subscribe for new securities (including directors’ and other executive options) Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security. 3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE (a) Purchases and sales Class of relevant securityPurchase/sale Number of securitiesPrice per unit (b) Derivatives transactions (other than options) Class of relevant securityProduct description e.g. CFDNature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short positionNumber of reference securitiesPrice per unit GBPGBP 0.1p ordinary CFDIncrease a long position39,941170.55GBP 0.1p ordinary CFDIncrease a long position38,121170.63 (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying Class of relevant securityProduct description e.g. call optionWriting, purchasing, selling, varying etc. Number of securities to which option relatesExercise price per unitType e.g. American, European etc.Expiry dateOption money paid/ received per unit (ii) Exercising Class of relevant securityProduct description e.g. call optionNumber of securitiesExercise price per unit (d) Other dealings (including subscribing for new securities) Class of relevant securityNature of dealing e.g. subscription, conversionDetailsPrice per unit (if applicable) The currency of all prices and other monetary amounts should be stated. Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in. 4. OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: If there are no such agreements, arrangements or understandings, state “none” (b) Agreements, arrangements or understandings relating to options or derivatives Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none” (c) Attachments Is a Supplemental Form 8 (Open Positions) attached ?NO Date of disclosure:13th May 2021Contact name: Deborah GewinnerTelephone number: +44 203 751 54 12 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at firstname.lastname@example.org. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk. Attachment 12.05.2021 Equiniti Group Plc
Maven, the dancer’s daughter with Countdown star Rachel Riley, was born in 2019.
The powerful antioxidants of this plant helps in concentration and calms your brain. It can be beneficial for students during their exam preparation. In other words, it is a brain tonic.
Some of the recently mentioned threats to its bottom line are illusory, but inexperienced investors could still fall for an upcoming trap.
The Government has agreed in principle to roll over the existing rights agreements with Sky Sports, BT Sport, Amazon Prime Video and BBC Sport.
Arsenal, Chelsea and Tottenham are in talks over holding a pre-season mini-tournament this summer instead of their usual overseas tours. Most of the income from the proposed friendlies would go to charity, helping the clubs to rebuild their reputations following their involvement in the European Super League fiasco. The games would take place between the end of the European Championship on July 14 and the start of the new Premier League season a month later.
Dublin, May 13, 2021 (GLOBE NEWSWIRE) -- The "Global Interactive Patient Engagement Solutions Market by Product (In Room Television, Interactive Bedside Terminals, Tablets), Type (Inpatient, Outpatient), End User (Hospitals, Clinics), Region - Forecast to 2026" report has been added to ResearchAndMarkets.com's offering. The interactive patient engagement solutions market is projected to reach USD 291 million by 2026 from USD 127 million in 2021, at a CAGR of 17.9%. The growth of this market is driven by the need for the adoption of improved interactive patient engagement solutions, a growing number of collaborations and partnerships between stakeholders, and favorable government regulations and initiatives to promote the adoption of these solutions. However, high infrastructural requirements and implementation costs and data security concerns are expected to restrain the growth of this market to a certain extent during the forecast period. In Room Television segment is expected to grow at the highest CAGR On the basis of product, the interactive patient engagement solutions market is segmented into in-room televisions, interactive bedside terminals/assistive devices, and tablets. In 2020, the in-room televisions segment accounted for the largest share of 51.5% of the global interactive patient engagement solutions market. The large share of this segment can be attributed to the rising development of TV-based solutions and the increased adoption of in-room televisions by hospitals. Inpatients more keen in adopting the interactive patient engagement solutions than outpatient On the basis of type, the interactive patient engagement solutions market is segmented into inpatient and outpatient solutions. In 2020, the inpatient solutions segment accounted for the largest share of 84.9% of the interactive patient engagement solutions market. The large share of this segment can be attributed to the need for improved patient care and favorable government initiatives for the adoption of these solutions. North America to witness significant growth from 2021 to 2026 In 2020, North America accounted for the largest share of 60.9% of the interactive patient engagement solutions market. This market is also expected to grow at the highest CAGR during the forecasted period. The large share and the high growth of this market can be attributed to favorable government initiatives, the rising prevalence of chronic diseases, and rising awareness about digital healthcare products. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights4.1 Interactive Patient Engagement Solutions Market Overview4.2 North America: Interactive Patient Engagement Solutions Market,By Type and Country (2020)4.3 Interactive Patient Engagement Solutions Market Share, by Type, 2021 Vs. 2026 5 Market Overview5.1 Introduction5.1.1 Drivers184.108.40.206 Need for the Adoption of Improved Interactive Patient Engagement Solutions220.127.116.11 Growing Number of Collaborations and Partnerships Between Stakeholders18.104.22.168 Favorable Government Regulations and Initiatives to Promote the Adoption of Hcit Solutions5.1.2 Restraints22.214.171.124 High Infrastructural Requirement and Implementation Costs126.96.36.199 Data Security Concerns Related to the Use of These Solutions5.1.3 Opportunities188.8.131.52 Emerging Countries Offer High-Growth Potential184.108.40.206 Technological Advancements5.1.4 Challenges220.127.116.11 Dearth of Skilled Professionals5.2 Impact of COVID-19 on the Interactive Patient Engagement Solutions Market5.3 Case Studies5.3.1 Focus on Reducing Readmission Rates and Improving Care18.104.22.168 Use Case 1: Need to Reduce Patient Stay5.3.2 Improve Outpatient Communication22.214.171.124 Use Case 2: Need to Curb Communication Issues with Discharged Patients5.4 Ecosystem Coverage5.5 Technology Analysis5.6 Regulations5.6.1 Health Insurance Portability and Accountability Act of 1996 (Hipaa)5.6.2 Health Information Technology for Economic and Clinical Health Act of 2009 (Hitech)5.6.3 Consumer Privacy Protection Act of 20175.6.4 National Cybersecurity Protection Advancement Act of 20155.6.5 Cybersecurity Law of the People's Republic of China5.6.6 Affordable Care Act, 20105.7 Pricing Analysis5.8 Market Survey Analysis: End-User Viewpoint 6 Interactive Patient Engagement Solutions Market, by Type6.1 Introduction6.2 Inpatient Solutions6.2.1 Need for Patient Involvement in Their Care Process to Support the Growth of this Market6.3 Outpatient Solutions6.3.1 Large Number of Outpatient Procedures Performed to Drive Market Growth 7 Interactive Patient Engagement Solutions Market, by Product7.1 Introduction7.2 In-Room Televisions7.2.1 Increasing Adoption of In-Room Televisions by Hospitals to Drive Market Growth7.3 Integrated Bedside Terminals/Assistive Devices7.3.1 Rising Adoption of Integrated Bedside Terminals to Enhance Patient Experience is Driving Market Growth7.4 Tablets7.4.1 Portability and Cost-Effectiveness of Tablets are Supporting Their Adoption 8 Interactive Patient Engagement Solutions Market, by End-user8.1 Introduction8.2 Hospitals8.2.1 Hospitals are the Largest and Fastest-Growing End-User Segment of the Interactive Patient Engagement Solutions Market8.3 Clinics8.3.1 Reduced Mortality Rates with the Usage of Interactive Bedside Solutions to Support Market Growth8.4 Other End-users 9 Interactive Patient Engagement Solutions Market, by Region9.1 Introduction9.2 North America9.3 Europe9.4 Asia-Pacific9.5 Rest of the World 10 Competitive Landscape10.1 Overview10.2 Market Player Ranking10.3 Competitive Leadership Mapping10.3.1 Stars10.3.2 Emerging Leaders10.3.3 Pervasive Players10.3.4 Participants10.4 Company Product Footprint10.5 Market Evaluation Framework10.6 Competitive Scenario 11 Company Profiles11.1 Getwellnetwork, Inc.11.2 Sonifi Health11.3 Allen Technologies, Inc.11.4 Advantech Co., Ltd.11.5 Hospedia Limited11.6 Evideon11.7 Aceso Interactive, Inc.11.8 Epic Systems Corporation11.9 Pdi Communication Systems, Inc.11.10 Lincor Solutions11.11 Clinicall11.12 Hopitel Inc.11.13 I3Solutions Inc.11.14 Healthhub Patient Engagement Solutions11.15 Arbor Technology Corp.11.16 Healthcare Information, LLC11.17 Bewatec Kommunikationstechnik GmbH11.18 Onyx Healthcare, Inc.11.19 Barco Nv11.20 Remedi Technology 12 Appendix12.1 Discussion Guide12.2 Knowledge Store: The Subscription Portal12.3 Available Customizations12.4 Related Reports12.5 Author Details For more information about this report visit https://www.researchandmarkets.com/r/4rnh8s CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
The "Mobile Data Protection Solution And Services Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029" report has been added to ResearchAndMarkets.com's offering.
A woman from Queensland is documenting her journey on TikTok after she said she woke up with an Irish accent following surgery on her tonsils at the end of April.Angela Yen, 27, told Storyful that she had a tonsillectomy on April 19, and was shocked 10 days later when she found herself speaking in an Irish accent.“I’ve never been to Ireland. I grew up in Australia and had an Aussie accent for the last 20 years since I moved here when I was eight years old,” she said.Dr Karl Kruszelnicki, a science communicator, said in a TikTok video that Yen may have foreign accent syndrome, a rare speech disorder that causes the person with it to sound like they are speaking with an accent from another country.In her most recent update, Yen hit back at a skeptical commenter, documenting the amount she could end up spending in medical bills while trying to get her Australian accent back. Credit: Angela Yen via Storyful
King will interview Barack Obama and one of the Queen's childhood friends for the show.
Relationships of Bollywood celebrities that ducked the paparazzi's eye.
Deterorating waiting lists now at their worst levels since 2007
Our Cookery Team pick the foodie Father's day hampers they'll be buying this year